FDA Review Of Novartis’ Tekturna Set Back Three Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay will allow agency to review new data on the impact of the first-in-class blood pressure medication on the colon.
You may also be interested in...
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
The first-in-class drug will launch later in March.
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
The first-in-class drug will launch later in March.
Tekturna Launch Anticipated “Very Quickly” Following Approval
Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.